MAP2K2 Monoclonal Antibody

SKU: E-AB-22162

Size: 200μL

Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date: 12 months

Category ID_II: Primary Antibodies

Category ID_III: Monoclonal Antibodies

Abbreviation: MEK2

Target Synonym: Cardiofaciocutaneous syndrome;CFC syndrome;CFC4;Dual specificity mitogen activated protein kinase kinase 2;Dual specificity mitogen-activated protein kinase kinase 2;ERK activator kinase 2;FLJ26075;MAP kinase kinase 2;map2k2;MAPK / ERK kinase 2;MAPK/ERK kinase 2;MAPKK 2;MAPKK2;MEK 2;MEK2;Microtubule associated protein kinase kinase 2;Mitogen activated protein kinase kinase 2;Mitogen activated protein kinase kinase 2 p45;MKK 2;MKK2;MP2K2;OTTHUMP00000165826;OTTHUMP00000165827;PRKMK 2;PRKMK2

Research Areas: Cancer;Signal Transduction

Conjugation: Unconjugated

Host: Mouse

Species reactivity: Human;Mouse;Rat

Application: WB

Isotype: IgG

Clonality: Monoclonal

Clone NO.: 2C3

UNIProt ID: P36507

Accession:

Background: The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.

Concentration: 1 mg/mL

Immunogen: Synthesized peptide derived from human MEK-2 around the non-phosphorylation site of T394.

Buffer: PBS with 0.02% sodium azide, 0.5% protective protein and 50% glycerol, pH7.4

Purification method: Protein A purification

Dilution: WB 1:500-1:2000;IHC 1:100-1:300;IP 1:200-1:500

Calculated MW:

ObservedMW: 45kDa